Global News

Interventional Concepts, ACRES ink alliance for Colombia

Friday, April 29, 2016

Interventional Concepts, a CRO for innovative pharma, biotech and medtech development-stage companies proposing to conduct clinical trials in Colombia, and the Alliance for Clinical Research Excellence and Safety (ACRES), a multi-sector nonprofit operating in the public interest and committed to transforming the global clinical research environment, have announced a strategic alliance, joining Interventional Concepts with current ACRES Allies in their efforts to build ACRES’ shared global clinical research system.

[Read More]

WCCT Global opens offices in Seoul, South Korea

Friday, April 29, 2016

WCCT Global, a full-service CRO, is announcing the opening of an office and clinical operations in Seoul, Korea. With the expansion of operations into South Korea, the company is poised to further establish itself as a global CRO. The expansion is a part of the company’s efforts to increase its capacity for conducting high quality clinical research in one of Asia’s fastest-growing countries for biopharmaceutical development.

[Read More]

AbbVie to acquire Stemcentrx for $5.8B

Friday, April 29, 2016

AbbVie has announced it will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T), currently in registrational trials for small cell lung cancer (SCLC). Rova-T is a novel biomarker-specific therapy that is derived from cancer stem cells and targets delta-like protein 3 (DLL3) that is expressed in more than 80% of SCLC patient tumors and is not present in healthy tissue. Registrational trials for third-line small cell lung cancer are expected to complete enrollment by the end of 2016.

[Read More]

Certara launches e-learning platform for biosimulation education

Thursday, April 28, 2016

Certara, a global biosimulation technology-enabled drug development company, has launched an e-learning platform through Certara University to satisfy the increased need for education in the burgeoning field of biosimulation or model-based drug development. With the addition of this new on-demand content, scientists from all over the world, with differing skill levels in biosimulation, will be able to access the educational assets developed by Certara’s scientific leaders. 

[Read More]